(3-溴-2-吡啶)-肼 | 54231-41-3

• 物质功能分类: 有机原料 - 肼或胲的有机衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: (3-溴-2-吡啶)-肼
• 中文别名: 3-溴-2-肼基吡啶
• 英文名称: 3-bromo-2-hydrazinylpyridine
• 英文别名: 3-bromo-2-hydrazinopyridine；(3-bromopyridin-2-yl)hydrazine
• CAS: 54231-41-3
• 化学式: C₅H₆BrN₃
• 分子量: 188.027
• InChiKey: DUQSXMSCIRLMCP-UHFFFAOYSA-N

物化性质

• 沸点：
  265.9±50.0 °C(Predicted)
• 密度：
  1.82±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  50.9
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 包装等级：
  III
• 危险类别：
  6.1
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P310+P330,P302+P352,P304+P340+P312,P305+P351+P338+P310,P332+P313,P403+P233,P405,P501
• 危险品运输编号：
  2811
• 危险性描述：
  H301,H315,H318,H335
• 储存条件：
  -20℃，避光

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Bromo-2-hydrazinopyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Bromo-2-hydrazinopyridine
CAS number: 54231-41-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H6BrN3
Molecular weight: 188.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (3-溴-2-吡啶)-肼 在 silver hexafluoroantimonate 、 四(三苯基膦)钯 、 bis[dichloro(pentamethylcyclopentadienyl)iridium(III)] 、 溶剂黄146 、 sodium nitrite 作用下， 以 水 、 间二甲苯 、 苯 为溶剂， 反应 38.5h， 生成 7-氮杂吲哚
  参考文献：
  名称：

  1,2,3,4-四唑通过电环化的 Ir 催化分子内环化/C(sp2)-H 胺化

  摘要：

  描述了一种对含有 C8 取代芳烃、杂芳烃和烯烃的 1,2,3,4-四唑进行分子内脱氮环化/C(sp2)-H 胺化的有效策略。该过程涉及通过 [Cp*IrCl2]2 和 AgSbF6 的组合从四唑生成金属-氮烯中间体。已经表明该反应通过前所未有的电环化过程进行。该方法已成功应用于合成各种 α-咔啉和 7-氮杂吲哚。

  DOI：

  10.1021/jacs.8b05343
• 作为产物：
  描述：

  3-溴-2-氯吡啶 以91%的产率得到(3-溴-2-吡啶)-肼
  参考文献：
  名称：

  发现作为人11β-羟基类固醇脱氢酶1（11β-HSD-1）抑制剂的临床候选药物BMS-823778。

  摘要：

  BMS-823778（2）是一种1,2,4-三唑并吡啶基-甲醇衍生的类似物，被确定为1β型11β-羟类固醇脱氢酶（11β-HSD-1）酶的强效和选择性抑制剂（IC50 = 2.3 nM）相对于11β-HSD-2具有> 10,000倍的选择性。化合物2在食蟹猴（ED50 = 0.6 mg / kg）和饮食诱发的肥胖（DIO）小鼠（ED50 = 34 mg / kg）中表现出强大的急性药效作用。化合物2在离体脂肪DIO小鼠模型中也显示出优异的抑制作用（ED50 = 5.2 mg / kg）。临床前物种的口服生物利用度范围为44％至100％。它具有良好的开发性能，药代动力学，高的脂肪对血浆浓度比以及临床前药理学特性，促使2期临床试验对2型糖尿病和代谢综合征的治疗进行了评估。

  DOI：

  10.1021/acsmedchemlett.8b00307
• 作为试剂：
  描述：

  3-溴-2-氯吡啶 、 肼 在 乙酸乙酯 、 Brine 、 magnesium sulfate 、 (3-溴-2-吡啶)-肼 作用下， 以 四氢呋喃 为溶剂， 反应 40.0h， 生成 (3-溴-2-吡啶)-肼
  参考文献：
  名称：

  Triazolopyridinone PDE10 inhibitors

  摘要：

  本发明涉及三唑吡啶酮化合物，其作为治疗与磷酸二酯酶10（PDE10）相关的中枢神经系统疾病的治疗剂。本发明还涉及使用这种化合物治疗神经系统和精神障碍，例如精神分裂症，精神病或亨廷顿病，以及与纹状体功能不足或基底节功能障碍相关的疾病。

  公开号：

  US09266881B2

文献信息

• [EN] IMIDAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS D'IMIDAZOLE
  申请人：MERCK SHARP & DOHME

  公开号：WO2012015693A1

  公开（公告）日：2012-02-02

  Described herein are compounds of formula (I) :The compounds of formula I act as DGAT1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.

  本文描述了化合物的结构式(I)：结构式I的化合物作为DGAT1抑制剂，可用于预防、治疗或作为高脂血症、糖尿病和肥胖的治疗药物。
• [EN] HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS<br/>[FR] HYDROXYMÉTHYLPYRROLIDINES EN TANT QU'AGONISTES DE RÉCEPTEUR BÊTA-3-ADRÉNERGIQUE
  申请人：MERCK & CO INC

  公开号：WO2009123870A1

  公开（公告）日：2009-10-08

  The present invention provides compounds of Formula I, pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

  本发明提供了式I的化合物，其药物组成物以及使用该化合物在治疗或预防由β3-肾上腺素受体激活介导的疾病的方法。
• [EN] BENZYL-, (PYRIDIN-3-YL)METHYL- OR (PYRIDIN-4-YL)METHYL-SUBSTITUTED OXADIAZOLOPYRIDINE DERIVATIVES AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS<br/>[FR] DÉRIVÉS D'OXADIAZOLOPYRIDINE À SUBSTITUTION BENZYLE, (PYRIDIN-3-YL)MÉTHYLE OU (PYRIDIN-4-YL)MÉTHYLE UTILISÉS EN TANT QU'INHIBITEURS DE LA GHRÉLINE O-ACYLTRANSFÉRASE (GOAT)
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2019149657A1

  公开（公告）日：2019-08-08

  The present invention relates to compounds of general formula (I), wherein the groups R1 and R2 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.

  本发明涉及一般式（I）的化合物，其中基团R1和R2的定义如权利要求1中所述，该化合物具有有价值的药理特性，特别是与胃饥饿素O-酰基转移酶（GOAT）结合并调节其活性。这些化合物适用于治疗和预防可以受到该受体影响的疾病，如代谢性疾病，特别是肥胖症。
• TRIAZOLOPYRIDINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS
  申请人：Li Jun

  公开号：US20090093516A1

  公开（公告）日：2009-04-09

  Novel compounds are provided which are 11 -beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula I: or stereoisomers or pharmaceutically acceptable salts thereof, wherein G, Q, X, Y, R 3 , R 3a , and R 3b are defined herein.

  提供了一种新的化合物，它们是11-β-羟基类固醇脱氢酶I型抑制剂。11-β-羟基类固醇脱氢酶I型抑制剂在治疗、预防或减缓需要11-β-羟基类固醇脱氢酶I型抑制剂治疗的疾病的进展方面是有用的。这些具有式I的新化合物： 或其立体异构体或药用可接受的盐，其中G、Q、X、Y、R3、R3a和R3b在此处被定义。
• A mild synthesis of [1,2,4]triazolo[4,3-a]pyridines
  作者：Michael A. Schmidt、Xinhua Qian

  DOI：10.1016/j.tetlet.2013.08.024

  日期：2013.10

  The reaction between 2-hydrazinopyridines and ethyl imidates was examined as a one-pot method for rapidly preparing [1,2,4]triazolo[4,3-a]pyridines. A diverse set of 2-hydrazinopyridines were cyclized with a variety of alkyl- and aryl-substituted ethyl imidates in good yields. The reaction proceeds optimally under mild conditions (50−70 °C) using 1.5 equiv of acetic acid. The electronic and steric

  作为快速制备[1,2,4]三唑并[4,3- a ]吡啶的一锅法，研究了2-肼基吡啶和酰亚胺乙酯之间的反应。用各种烷基取代基和芳基取代的乙基酰亚胺酯以高收率将各种不同的2-肼基吡啶环化。使用1.5当量的乙酸，在温和的条件下（50-70°C），反应可以最佳地进行。肼和亚氨酸酯的电子和位阻性质强烈影响反应速率。当使用高度缺乏电子的2-肼基吡啶时，产物重排为[1,2,4]三唑并[1,5- a ]吡啶。